Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive
On January 4, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its CEO, Lalo Flores, Ph.D., will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. The event will cover the company's advancements in iPSC-derived cell therapies for cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterward. Century Therapeutics focuses on harnessing stem cells to improve patient care in oncology.
Century Therapeutics (NASDAQ: IPSC) has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI), effective December 20, 2021. This index tracks companies in the biotechnology and pharmaceuticals segment, requiring a minimum market capitalization of $200 million and an average trading volume of at least 100,000 shares. Being part of the index can enhance visibility and attract institutional investments. Century Therapeutics focuses on developing iPSC-derived cell therapies targeting cancers, aiming to facilitate broader patient access and improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) presented promising preclinical data for its CNTY-101 program at the ASH Annual Meeting, showing strong antitumor activity against human lymphoma cell lines. The company plans to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory lymphoma with an IND submission on track for mid-2022. The data support the use of γδ CAR-iT cells, which do not present a GVHD risk, marking a significant advancement in their iPSC-derived T cell therapies.
Century Therapeutics (NASDAQ: IPSC) announced the participation of its senior management in a fireside chat ahead of the Piper Sandler 33rd Annual Virtual Healthcare Conference, scheduled for November 30 to December 2, 2021. A recording of the chat will be available today at 10:00 AM ET on the Events & Presentations section of Century's website, accessible for 30 days. The company focuses on developing iPSC-derived cell therapies aimed at overcoming challenges in cancer treatment.
Century Therapeutics (NASDAQ: IPSC) reported third-quarter financial results showing a net loss of $26 million, up from $13.1 million a year prior. Cash and equivalents decreased to $400.3 million from $440 million. Despite this, the company remains on track with its lead program, CNTY-101, for a mid-2022 IND filing. Notable investments have been made in manufacturing and R&D, with R&D expenses rising to $19.5 million due to increased personnel and study costs. A collaboration with Outpace Bio aims to enhance their iPSC therapy platform.
Century Therapeutics (NASDAQ: IPSC) announced the presentation of preclinical data from its CNTY-101 program at the 63rd American Society of Hematology Annual Meeting, taking place December 11-14, 2021, in Atlanta and virtually. The company will also host a virtual R&D update on December 16, 2021, featuring discussions on B-cell malignancies by Dr. Eduardo Sotomayor. Key poster presentations include iPSC-derived CAR-NK cells and Gamma Delta CAR-T cells for cancer immunotherapy, aiming to address limitations in current therapies.
Century Therapeutics (NASDAQ: IPSC) has announced a research collaboration with Outpace Bio focusing on enhanced CAR engineering for immuno-oncology. This partnership aims to optimize CAR functionality using Outpace's advanced protein design and synthetic biology technologies. The initial program will target hematological malignancies, with potential for future expansion. Century's CEO emphasized the importance of innovative cell engineering to advance next-generation therapies, while Outpace's CEO highlighted the collaboration's potential to improve the efficacy of T cell therapies.
Century Therapeutics (NASDAQ: IPSC) announced its inclusion in the Russell 2000 Index, effective September 20, 2021. This milestone highlights the company's progress in developing iPSC-derived cell therapies for cancer treatment. The Russell 2000 Index represents small-cap stocks and is used by investors and funds to benchmark performance. CEO Lalo Flores expressed optimism about reaching a broader investor base as the company advances its lead therapeutic program, CNTY-101, into clinical stages. The Russell Index includes approximately $10.6 trillion in assets.
Century Therapeutics (NASDAQ: IPSC) reported its second-quarter financial results for 2021, highlighting significant developments and financial positions. The company raised approximately $221 million in a recent IPO, with cash, cash equivalents, and marketable securities totaling $440 million as of June 30, 2021. R&D expenses increased to $18.9 million, while G&A expenses rose to $4.1 million. The net loss for the quarter was $23.3 million, compared to $15.3 million in Q2 2020. The lead program, CNTY-101, is on track for IND filing in mid-2022.